title: [Comparison of the degree of regression of small cell lung neoplasm in clinical-radiologic evaluation with levels of neuron specific enolase (NSE) in serum].
abstract: NSE was estimated using Pharmacia test and radioimmunologic method in the serum of 41 SCLC patients before treatment, at the time of maximal tumor response and in some patients also during progression. The level of 12,5 ng/l was regarded as the upper limit of normal. Elevated NSE levels before treatment were found in 12 out of 20 patients with limited disease and in 19 out of 21 patients with extensive disease. Complete remission (CR) was observed only in patients with limited disease and in those in whom NSE serum level was below 50 ng/l. Elevated NSE serum levels decreased in all those in whom partial remission (PR) or CR of tumor was obtained. Decrease of elevated NSE levels was however also observed in some patients with no significant regression of tumor. The decrease of serum NSE level seemed to be a good prognostic factor even in this last group. NSE serum level increased in 7 out 10 patients where progressive disease after PR was found. In 3 patients however NSE level persisted in normal values despite progression. The significance of this fact was discussed.
authors.affiliation: III Kliniki Gruźlicy i Chorób Płuc, Instytutu Gruźlicy i Chorób Płuc w Warszawie.
authors.forename: E
authors.initials: E
authors.lastname: Rowińska-Zakrzewska
authors.forename: M
authors.initials: M
authors.lastname: Szturmowicz
authors.forename: A
authors.initials: A
authors.lastname: Sakowicz
authors.forename: L
authors.initials: L
authors.lastname: Pawlicka
authors.forename: P
authors.initials: P
authors.lastname: Remiszewki
authors.forename: J
authors.initials: J
authors.lastname: Szopiński
authors.forename: E
authors.initials: E
authors.lastname: Wiatr
authors.forename: J
authors.initials: J
authors.lastname: Zych
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D018288:Carcinoma, Small Cell / Q000201:enzymology* / Q000628:therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D010751:Phosphopyruvate Hydratase / Q000097:blood*; D011379:Prognosis; D012074:Remission Induction
chemical_list: D014408:Biomarkers, Tumor; D010751:Phosphopyruvate Hydratase